Daiichi Sankyo Launches Ranmark for Treatment of Bone Lesions Associated with Cancer; AZ to Copromote Product

Ranmark SC Injection 120 mg Launched by Daiichi Sankyo on April 17 Daiichi Sankyo launched its first antibody drug, the anti-RANKL (RANK ligand) antibody Ranmark SC Injection 120 mg (recombinant denosumab), on April 17. The product will be copromoted with...read more